TNXP Stock Analysis: Buy, Sell, or Hold?
TNXP - Tonix Pharmaceuticals Holding Corp.
$11.07
-0.81 (-6.82%)
▼
5d:
-10.22%
30d:
-24.64%
90d:
-17.7%
HOLD
MODERATE Confidence
Analysis Updated: Jun 5, 2026 12:00 AM ET
Earnings: May 18, 2026
0d
Get Alerted When TNXP Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
7 traders called TNXP this week
90% bullish • 1 bearish
90% bullish • 1 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: TNXP shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: TNXP shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: TNXP is currently trading at $11.07, which is considered oversold relative to its 30-day fair value range of $12.12 to $14.25.
Technical Outlook: Technically, TNXP is in a strong downtrend. The price is currently testing key support at $11.31. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 6.8% recently.
Market Sentiment: TNXP has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $46.25 (+317.8%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, TNXP is in a strong downtrend. The price is currently testing key support at $11.31. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 6.8% recently.
Market Sentiment: TNXP has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $46.25 (+317.8%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$12.12 -
$14.25
Company Quality Score
47/100
(HOLD)
Options IV Signal
32th percentile
(NORMAL)
Volume Confirmation
HIGH
Confidence Score
56.2%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Options fairly priced (IV 32th percentile)
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-6.8%)
- BULLISH: Trading 317.8% below Wall St target ($46.25)
- CAUTION: 5-day price weakness (-10.2%) - monitor closely
Trading Range Analysis
30-Day Trading Range
$12.12 -
$14.25
Current vs Trading Range
OVERSOLD
Expected Move (7 Days)
±$2.15
(19.4%)
Support & Resistance Levels
Support Level
$11.31
Resistance Level
$14.71
Current Trend
Strong Downtrend
Technical data as of
Jun 3, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.42
Wall Street Target
$46.25
(+317.8%)
Revenue Growth (YoY)
183.2%
Share & Embed Analysis
Last updated: June 06, 2026 5:25 AM ET
Data refreshes hourly during market hours. Next update: 6:25 AM
Data refreshes hourly during market hours. Next update: 6:25 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is TNXP showing a specific setup today?
Insider Activity (6 Months)
1
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
Seth Lederman
BUY
15000 shares
2026-03-18
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$27 | 53 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$412 | 53 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$270 | 63 BUY |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$108 | 67 BUY |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$102 | 61 BUY |
